Stock Track | OPKO Health Plunges 5.44% as Q3 Sales Miss Estimates

Stock Track

Nov 08, 2024

OPKO Health Inc. (NASDAQ: OPK) saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.

The biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure represented a 2.8% decline compared to the same period in the previous year.

The disappointing sales performance, which fell below both analyst projections and the company's own year-ago results, appears to be the primary driver behind OPKO Health's stock price decline. Investors may have reacted negatively to the weaker-than-expected revenue growth, which could raise concerns about the company's business momentum and future prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1110085337"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110085337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110085337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110085337","market":"hk","top_or_hot":-1,"title":"Stock Track | OPKO Health Plunges 5.44% as Q3 Sales Miss Estimates","media":"Stock Track","content":"<p>OPKO Health Inc. (NASDAQ: OPK) saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.</p>\n\n<p>The biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure represented a 2.8% decline compared to the same period in the previous year.</p>\n\n<p>The disappointing sales performance, which fell below both analyst projections and the company's own year-ago results, appears to be the primary driver behind OPKO Health's stock price decline. Investors may have reacted negatively to the weaker-than-expected revenue growth, which could raise concerns about the company's business momentum and future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | OPKO Health Plunges 5.44% as Q3 Sales Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | OPKO Health Plunges 5.44% as Q3 Sales Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 05:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>OPKO Health Inc. (NASDAQ: OPK) saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.</p>\n\n<p>The biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure represented a 2.8% decline compared to the same period in the previous year.</p>\n\n<p>The disappointing sales performance, which fell below both analyst projections and the company's own year-ago results, appears to be the primary driver behind OPKO Health's stock price decline. Investors may have reacted negatively to the weaker-than-expected revenue growth, which could raise concerns about the company's business momentum and future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"","article_id":"1110085337","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110085337","pubTimestamp":1731016481,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"OPKO Health Inc.  saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.The biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure repre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health"},"translate_title":"第三季度销售额未达预期，OPKO Health股价暴跌5.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPK":1},"content_text":"OPKO Health Inc. (NASDAQ: OPK) saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.\nThe biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure represented a 2.8% decline compared to the same period in the previous year.\nThe disappointing sales performance, which fell below both analyst projections and the company's own year-ago results, appears to be the primary driver behind OPKO Health's stock price decline. Investors may have reacted negatively to the weaker-than-expected revenue growth, which could raise concerns about the company's business momentum and future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}